About Royalty Pharma
Royalty Pharma is a private equity firm founded in 1996. It is primarily based in New York City, United States. As of Sep 2026, Royalty Pharma is an active investor with a portfolio of 55 companies, comprising 55 funding rounds and 4 acquisitions. In the last 12 months, it has participated in 1 funding round. The firm primarily invests in companies based in United States and Switzerland. Its portfolio is spread across a wide range of sectors from Healthcare to Life Sciences. Its latest investment was a $***** Series B round in Kailera on Oct 14, 2025 which also saw participation from Bain Capital Private Equity, Adage Capital Management and other investors.
A lot of funds co-invest with Royalty Pharma, with names like Sixth Road Consulting sharing a substantial percentage of its portfolio.
Royalty Pharma has a team of 56 people, including 9 partners.
Key Metrics
Founded Year
1996
Location
New York City, United States
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Royalty Pharma's Portfolio
Royalty Pharma has a portfolio of 55 companies. They have invested in a total of 55 companies. Their most recent investment was in Kailera (Series B round) on Oct 14, 2025. Here are the most recent investments by Royalty Pharma:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Oct 14, 2025 | Series B | 3669 | ||
Aug 08, 2024 | Series C | 7221 | ||
Jun 30, 2022 | Post IPO | 7305 | ||
Apr 15, 2022 | Series D | 2150 |
Royalty Pharma has acquired 4 companies. Their most recent acquisition was of Minerva Neurosciences on Jan 21, 2021. Here are the most recent acquisitions by Royalty Pharma:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Jan 21, 2021 | Innovating central nervous system disorder treatments with clinical expertise and patient focus | - | 2007 | |
Dec 18, 2019 | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 2010 | |
Apr 01, 2019 | Provider of patient healthcare services | - | 2016 | |
Dec 15, 2010 | Drugs for patients suffering from a variety of disorders of the central nervous system | - | 1981 |
Here is the portfolio snapshot of Royalty Pharma:
Investments by Year
The maximum number of investments were made in 2024
Acquisitions by Year
The maximum number of acquisitions were made in 2019
Portfolio by Location
Companies are primarily in United States and Switzerland
Portfolio by Sector
Companies are primarily in Healthcare
Team profile of Royalty Pharma
Royalty Pharma has a team of 56 members including 9 Partners and 25 Principals located in United States. Royalty Pharma's team does not sit on the board of any company as of now.Here is a list of top team members in Royalty Pharma:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Burlingame | - | ||
Partner | New York City | - | ||
Partner | - | - | ||
Partner | New York | - | ||
Partner | Princeton | - | ||
Partner | New Haven | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Principal | New York City | - | ||
Principal | New York City | - |
Co-investors of Royalty Pharma
Over the past 30 years, 19 investors have co-invested in Royalty Pharma's portfolio companies.
- Top Co-investors of Royalty Pharma: 19 investors entered a company along with Royalty Pharma. These include investors like Sixth Road Consulting (1 company).
Royalty Pharma News
•
Novartis Lp(a)HORIZON Phase III Trial Misses Primary EndpointGlobeNewswire•Sep 05, 2026•Novartis, Ionis, Royalty Pharma
•
•
•
Royalty Pharma Appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesGlobeNewswire•Aug 03, 2026•Royalty Pharma
•
Neurimmune Closes Licensing Deal of Up to USD425 MillionStartupticker•Jul 22, 2026•Neurimmune, AstraZeneca, Royalty Pharma
•
•
•
•
•
Thrivent Financial for Lutherans Acquires 22,015 Shares of Royalty Pharma PLCMarketBeat•May 20, 2026•Royalty Pharma, Thrivent
